Bessemer Group
FLNA

Bessemer Group’s Filana Therapeutics FLNA Stock Holding History

Bessemer Group’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
24
– – ﹤0.01% 2661
2025
Q4 		$0 Hold
24
– – ﹤0.01% 2692
2025
Q3 		$0 Buy
+24
New +$55 ﹤0.01% 2697
2024
Q4 		– Sell
-55
Closed -$2K – 2661
2024
Q3 		$2K Buy
+55
New +$1.27K ﹤0.01% 2262
2022
Q3 		– Sell
-150
Closed -$4K – 2148
2022
Q2 		$4K Hold
150
– – ﹤0.01% 1624
2022
Q1 		$6K Hold
150
– – ﹤0.01% 1482
2021
Q4 		$7K Hold
150
– – ﹤0.01% 1507
2021
Q3 		$9K Hold
150
– – ﹤0.01% 1412
2021
Q2 		$13K Buy
+150
New +$8.04K ﹤0.01% 1299

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Bessemer Group's FLNA Position: Q1 2026 in Review

Bessemer Group held its Filana Therapeutics (FLNA) position steady in Q1 2026 at 24 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2661.

Bessemer Group first reported a position in FLNA in Q2 2021 and has held it in 9 quarters since. The position peaked at $13K in Q2 2021. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • Bessemer Group held 24 shares of Filana Therapeutics worth $0 as of Q1 2026.
  • Bessemer Group left its Filana Therapeutics share count unchanged in Q1 2026.
  • Filana Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #2661 holding.
  • Bessemer Group first reported a position in Filana Therapeutics in Q2 2021 and has held it in 9 quarters since.
  • Bessemer Group's Filana Therapeutics position peaked at $13K in Q2 2021.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.